Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2014—Laboratories performing food and environmental testing, clinical research, forensic toxicology, pharmaceutical or biopharmaceutical measurements, and other applied analyses can now benefit from the performance of high-resolution accurate-mass (HRAM) Orbitrap mass spectrometry using an instrument designed for cost-per-sample-sensitive workflows.
December 2014—MyCartis announced the launch of Evalution, a digital multiplex analysis platform tailored to clinical research and pharmaceutical markets and designed to analyze a broad range of protein and nucleic-acid-based biomarkers. Evalution provides an integrated reaction and detection environment and simultaneous analysis of large numbers of analytes per assay.
December 2014—The Thermo Scientific XBF40 series of -40°C blast freezers are for rapid cooling during the sample preparation process, prior to freezer storage. Available in two options, the XBF40D-MD is designed for rapid plasma freezing and accommodates plasma bags, boxes, and bottles, and the XBF40D is for general-purpose applications and accommodates staggered loads and a variety of vessels, such as carboys, bottles, racks with vials, and more.
December 2014—EKF Diagnostics announced it has entered a two-year research collaboration with Massachusetts General Hospital to develop PointMan assays that can detect treatable cancer mutations in blood samples. MGH will use PointMan DNA for the detection of genetic variation in circulating tumor cells isolated from a patient’s blood using MGH’s CTC-Chip instrument.
December 2014—Streck’s A1c-Cellular Linearity, an HbA1c linearity/calibration verification material with intact red blood cells, is now assayed for the Trinity Biotech Premier Hb9210 and Ultra2 instruments. A1c-Cellular Linearity is a five-level assayed linearity material used to assess instrument accuracy and verify the patient reportable range of the HbA1c parameter.
December 2014—Horizon Discovery Group announced it has agreed to acquire Sage Labs for up to $16 million in cash and up to $32 million through the issue of new ordinary shares. The acquisition of Sage, a provider of next-generation research models, builds on the acquisition of CombinatoRx in July.
December 2014—To support users focused on hereditary disease, Qiagen has fully integrated Biobase HGMD Professional with Ingenuity Variant Analysis so that researchers no longer require a separate human gene mutation database license. The Ingenuity Variant Analysis is a Web-based software application that filters genetic variants in a secure, private, cloud-based environment to identify variants most likely to cause disease.
December 2014—DuraClone IM premixed dry reagent cocktails from Beckman Coulter Life Sciences standardize and streamline workflow for high-content flow cytometry in translational research studies involving identification of cellular subpopulations of the human immune system.
December 2014—Royal Philips announced it has acquired the CE mark for the diagnostic use of its Philips Digital Pathology Solution. European pathologists will now be able to use the full digital solution as an aid in diagnosis for routine pathology, including hematoxylin and eosin, immunohistochemistry, and special stained tissue sections.
December 2014—The PathScope 2 microscope imaging system from SPOT Imaging Solutions is designed to save pathologists up to two minutes per slide by streamlining routine slide examination. One click of the HistoSnap button captures the image during slide examination and imprints the image with the case number and reference mark, and then archives it to the laboratory information system, file server, or cloud storage.
